Quetiapine versus typical antipsychotic medications for schizophrenia

作者: Sirijit Suttajit , Manit Srisurapanont , Jun Xia , Siritree Suttajit , Benchalak Maneeton

DOI: 10.1002/14651858.CD007815.PUB2

关键词:

摘要: Background Quetiapine is a widely used atypical antipsychotic drug for schizophrenia that has been on the market over decade. However, It not clear how effects of quetiapine differ from typical antipsychotics. Objectives To review in comparison with antipsychotics treatment and schizophrenia-like psychosis. Search methods We searched Cochrane Schizophrenia Group Trials Register (March 2010), inspected references all identified studies. Selection criteria We included randomised control trials comparing oral drugs people or psychosis. Data collection analysis We extracted data independently. For dichotomous data, we calculated risk ratio (RR) 95% confidence intervals (CI) using random-effects model. We presented chosen outcomes 'Summary findings' table comparative risks where appropriate. continuous mean differences (MD) based assessed bias studies. Main results The includes 43 controlled (RCTs) 7217 participants. Most studies were China. The percentages participants leaving early similar (36.5% group 36.9% group) no significant difference between groups was apparent due to any reason (23 RCTs n = 3576 RR 0.91 CI 0.81 1.01, moderate quality evidence), however, fewer left adverse events (15 RCTs, 3010, 0.48 0.30 0.77). Overall global state (no clinically response; 16 1607, 0.96 0.75 1.23, evidence) there positive symptoms (PANSS subscore: 22 1934, MD 0.02 -0.39 0.43, evidence). General psychopathology equivocal general 18 1569, -0.20 -0.83 0.42) those allocated antipsychotics. statistically significantly more efficacious negative -0.82 -1.59 -0.04, this result highly heterogeneous driven by two small outlier high effect sizes. Without these studies, heterogeneity antipsychotics. Compared antipsychotics, might cause (9 1985, 0.76 0.64 0.90 number needed treat induce harm (NNTH) 10, 8 17), less abnormal ECG (2 165, 0.38 0.16 0.92, NNTH 8, 4 55), overall extrapyramidal (8 1,095, 0.17 0.09 0.32, 3, 3 specific including akathisia, parkinsonism, dystonia tremor. Moreover, it lower prolactin level (4 1034, -16.20 -23.34 -9.07, weight gain compared some short term 866, 0.52 0.34 0.80, 6 15). However, suicide attempt, suicide, death, QTc prolongation, low blood pressure, tachycardia, sedation, gynaecomastia, galactorrhoea, menstrual irregularity white cell count. Authors' conclusions Quetiapine may psychopathology. There are terms symptoms. causes ECG, effects, levels gain.

参考文章(97)
J. Peuskens, C. G. G. Link, A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia Acta Psychiatrica Scandinavica. ,vol. 96, pp. 265- 273 ,(1997) , 10.1111/J.1600-0447.1997.TB10162.X
Ukoumunne, Gulliford, Chinn, Sterne, Burney, Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment. ,vol. 3, ,(1999) , 10.3310/HTA3050
Robert E. McCue, Rubina Waheed, Leonel Urcuyo, Geraldine Orendain, Michel D. Joseph, Richard Charles, Syed M. Hasan, Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. British Journal of Psychiatry. ,vol. 189, pp. 433- 440 ,(2006) , 10.1192/BJP.BP.105.019307
Julian PT Higgins, Simon G Thompson, Jonathan J Deeks, Douglas G Altman, Measuring inconsistency in meta-analyses BMJ. ,vol. 327, pp. 557- 560 ,(2003) , 10.1136/BMJ.327.7414.557
Dawn.I. Velligan, John Newcomer, Joseph Pultz, John Csernansky, Anne L. Hoff, Roderick Mahurin, Alexander.L. Miller, Does cognitive function improve with quetiapine in comparison to haloperidol Schizophrenia Research. ,vol. 53, pp. 239- 248 ,(2002) , 10.1016/S0920-9964(01)00268-7
Kevin E. Thorpe, Merrick Zwarenstein, Andrew D. Oxman, Shaun Treweek, Curt D. Furberg, Douglas G. Altman, Sean Tunis, Eduardo Bergel, Ian Harvey, David J. Magid, Kalipso Chalkidou, A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers Journal of Clinical Epidemiology. ,vol. 62, pp. 464- 475 ,(2009) , 10.1016/J.JCLINEPI.2008.12.011
Diana R Elbourne, Douglas G Altman, Julian PT Higgins, Francois Curtin, Helen V Worthington, Andy Vail, Meta-analyses involving cross-over trials: methodological issues International Journal of Epidemiology. ,vol. 31, pp. 140- 149 ,(2002) , 10.1093/IJE/31.1.140
Allan Donner, Neil Klar, Issues in the meta-analysis of cluster randomized trials Statistics in Medicine. ,vol. 21, pp. 2971- 2980 ,(2002) , 10.1002/SIM.1301
S. Priebe, P. Huxley, S. Knight, S. Evans, Application and Results of the Manchester Short Assessment of Quality of Life (Mansa) International Journal of Social Psychiatry. ,vol. 45, pp. 7- 12 ,(1999) , 10.1177/002076409904500102
Stephan Heres, John Davis, Katja Maino, Elisabeth Jetzinger, Werner Kissling, Stefan Leucht, Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics American Journal of Psychiatry. ,vol. 163, pp. 185- 194 ,(2006) , 10.1176/APPI.AJP.163.2.185